Literature DB >> 26644327

Dose-associated pulmonary complication rates after fresh frozen plasma administration for warfarin reversal.

A L Marshall1, M Levine2, M L Howell3, Y Chang3, E Riklin3, B A Parry3, R T Callahan3, I Okechukwu3, A M Ayres3, B V Nahed3, J N Goldstein3.   

Abstract

UNLABELLED: ESSENTIALS: Fresh frozen plasma (FFP) may be associated with a dose-based risk of pulmonary complications. Patients received FFP for warfarin reversal at a large academic hospital over a 3-year period. Almost 20% developed pulmonary complications, and the risk was highest after > 3 units of FFP. The risk of pulmonary complications remained significant in multivariable analysis.
BACKGROUND: Fresh frozen plasma (FFP) is often administered to reverse warfarin anticoagulation. Administration has been associated with pulmonary complications, but it is unclear whether this risk is dose-related. Aims We sought to characterize the incidence and dose relationship of pulmonary complications, including transfusion-associated circulatory overload (TACO) and transfusion-related acute lung injury (TRALI), after FFP administration for warfarin reversal.
METHODS: We performed a structured retrospective review of patients who received FFP for warfarin reversal in the emergency department (ED) of an academic tertiary-care hospital over a 3-year period. Logistic regression was used to explore the relationship between FFP dose and risk of pulmonary events.
RESULTS: Two hundred and fifty-one patients met the inclusion criteria. Overall, 49 patients (20%) developed pulmonary complications, including 30 (12%) with TACO, two (1%) with TRALI, and 17 (7%) with pulmonary edema not meeting the criteria for TACO. Pulmonary complications were significantly more frequent in those who received > 3 units of FFP (34.0% versus 15.6%, 95% confidence interval for risk difference 7.9%-8.9%). After stratification by subtype of complication, only the risk of TACO was statistically significant (28.3% versus 7.6%, 95% confidence interval for risk difference 8.2%-16.6%). In multivariable analysis controlling for age, sex, initial systolic blood pressure, and intravenous fluids given in the ED, > 3 units of FFP remained a significant risk factor for pulmonary complications (odds ratio 2.49, 95% confidence interval 1.21-5.13).
CONCLUSIONS: Almost 20% of patients who received FFP for warfarin reversal developed pulmonary complications, primarily TACO, and this risk increased with > 3 units of FFP. Clinicians should be aware of and prepared to manage these complications.
© 2015 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  blood component transfusion; fresh frozen plasma; pulmonary edema; warfarin

Mesh:

Substances:

Year:  2016        PMID: 26644327     DOI: 10.1111/jth.13212

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  10 in total

1.  Single-Center Use of Prothrombin Complex Concentrate in Pediatric Patients.

Authors:  Takaharu Karube; Courtney Andersen; Joseph D Tobias
Journal:  J Pediatr Intensive Care       Date:  2020-01-10

2.  [Anesthesiological aspects of liver transplantation].

Authors:  S Dehne; F Lund; J Larmann; K Schmidt; T Brenner; M A Weigand; R von Haken
Journal:  Anaesthesist       Date:  2019-06       Impact factor: 1.041

3.  Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department.

Authors:  Michelle Maguire; Lanting Fuh; Joshua N Goldstein; Ariela L Marshall; Michael Levine; Melissa L Howell; Blair A Parry; Rachel Rosovsky; Bryan D Hayes
Journal:  West J Emerg Med       Date:  2019-06-11

4.  Volume incompliance and transfusion are essential for transfusion-associated circulatory overload: a novel animal model.

Authors:  Robert B Klanderman; Joachim J Bosboom; Adrie A W Maas; Joris J T H Roelofs; Dirk de Korte; Robin van Bruggen; Jaap D van Buul; Coert J Zuurbier; Denise P Veelo; Markus W Hollmann; Margreeth B Vroom; Nicole P Juffermans; Bart F Geerts; Alexander P J Vlaar
Journal:  Transfusion       Date:  2019-11-07       Impact factor: 3.157

5.  Active surveillance of serious adverse events following transfusion of COVID-19 convalescent plasma.

Authors:  Erica Swenson; Lisa Kanata Wong; Perrin Jhaveri; Yingjie Weng; Shanthi Kappagoda; Suchitra Pandey; Angelica Pritchard; Angela Rogers; Stephen Ruoss; Aruna Subramanian; Hua Shan; Marie Hollenhorst
Journal:  Transfusion       Date:  2021-10-22       Impact factor: 3.337

Review 6.  Application of fresh frozen plasma transfusion in the management of excessive warfarin-associated anticoagulation.

Authors:  Yuanyuan Luo; Chunya Ma; Yang Yu
Journal:  Blood Sci       Date:  2022-05-17

7.  Prothrombin complex concentrate versus placebo, no intervention, or other interventions in critically bleeding patients associated with oral anticoagulant administration: a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.

Authors:  Christian Ovesen; Jan Purrucker; Christian Gluud; Janus Christian Jakobsen; Hanne Christensen; Thorsten Steiner
Journal:  Syst Rev       Date:  2018-10-20

Review 8.  Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO.

Authors:  Meghan M Chlebowski; Sirine Baltagi; Mel Carlson; Jerrold H Levy; Philip C Spinella
Journal:  Crit Care       Date:  2020-01-20       Impact factor: 9.097

9.  Reversal of warfarin-coagulopathy: How to improve plasma transfusion practice in a community hospital setting?

Authors:  Lubna Bashir Munshi; Braghadheeswar Thyagarajan; Aasems Jacob; Shil Patel; Steve Zheng Liu; Arpad Szallasi
Journal:  Asian J Transfus Sci       Date:  2019-12-03

10.  Colloid osmotic pressure of contemporary and novel transfusion products.

Authors:  Robert B Klanderman; Joachim J Bosboom; Herbert Korsten; Thomas Zeiler; Ruben E A Musson; Denise P Veelo; Bart F Geerts; Robin van Bruggen; Dirk de Korte; Alexander P J Vlaar
Journal:  Vox Sang       Date:  2020-05-06       Impact factor: 2.144

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.